VISTAGEN THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$22.00K.
- VISTAGEN THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $30.00K, a 60.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $29.00K.
- VISTAGEN THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 9 month as first filed | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | ||||
| 2025-09-30 | -$22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $8.00K 10-Q · filed 2025-11-13 | $8.00K derived: sum of 3 quarters · filed 2026-08-14 | $8.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $30.00K 10-Q · filed 2026-08-14 | $30.00K derived: sum of 2 quarters · filed 2026-08-14 | $30.00K derived: sum of 3 quarters · filed 2026-08-14 | -$45.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | $0.00 derived: sum of 2 quarters · filed 2025-06-17 | -$75.00K derived: sum of 3 quarters · filed 2025-11-13 | $0.00 10-K · filed 2025-06-17 | |
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | -$75.00K derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-02-13 | $11.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-09-30 | -$75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $11.00K derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $75.00K 10-Q · filed 2025-08-07 | $86.00K derived: sum of 2 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | $29.00K 10-K · filed 2025-06-17 | |||
| 2023-12-31 | $18.00K 10-Q · filed 2025-02-13 | $17.90K 10-Q · filed 2024-02-13 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 2 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-11 | $0.00 10-K · filed 2024-06-11 | |||
| 2022-12-31 | $0.00 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |